Ginkgo Bioworks, a cell programming platform, has purchased Bitome, a company focused on real-time metabolite monitoring.

Bitome’s technology will support product development timelines across Ginkgo’s portfolio of cell programs.

“Ginkgo is constantly looking for opportunities to strengthen its cell engineering platform, and a central component of cell engineering is testing and optimizing strains at scale,” said Barry Canton, co-founder at Ginkgo Bioworks. “Having evaluated Bitome’s technology over the past few years, we believe their technology will allow us to accelerate the design and optimization of strains across a range of customers and industries.”